Laser Therapy Following Radiotherapy for Gynecological Cancer
Raktažodžiai
Santrauka
Datos
Paskutinį kartą patikrinta: | 06/30/2019 |
Pirmasis pateikimas: | 10/13/2018 |
Numatytas registravimas pateiktas: | 10/17/2018 |
Pirmas paskelbtas: | 10/21/2018 |
Paskutinis atnaujinimas pateiktas: | 07/27/2019 |
Paskutinis atnaujinimas paskelbtas: | 07/29/2019 |
Faktinė studijų pradžios data: | 11/14/2018 |
Numatoma pirminio užbaigimo data: | 05/31/2021 |
Numatoma studijų užbaigimo data: | 05/31/2021 |
Būklė ar liga
Intervencija / gydymas
Device: Microablative Fractional CO2 Laser Therapy
Fazė
Rankų grupės
Ranka | Intervencija / gydymas |
---|---|
Experimental: Laser Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.) | |
Placebo Comparator: Placebo Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode. |
Tinkamumo kriterijai
Tinkamos studijoms lytys | Female |
Priima sveikus savanorius | Taip |
Kriterijai | Inclusion Criteria: - History of gynecological cancer treated with pelvic radiotherapy - last radiotherapy >1 year - women sexually active or willing to resume sexual activity - symptoms of dyspareunia, vaginal dryness, itching/burning and vaginal bleeding related to sexual intercourse Exclusion Criteria: - Relapse of gynecological cancer - prolapse stage >1 - active genital infection (i.e herpes, vaginitis) - underlying pathologies that could interfere with patients compliance to the protocol (i.e any psychiatric condition) |
Rezultatas
Pirminės rezultatų priemonės
1. 10-centimeter Visual Analogue Scale assessing intensity of dyspareunia and dryness [Change from baseline at 1 month post-treatment]
Antrinės rezultatų priemonės
1. 3 days voiding diary [Change from baseline at 1 month post-treatment]
2. Day-to Day Impact of vaginal aging questionnaire (DIVA) [Change from baseline at 1 month post-treatment]
3. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ) cervical cancer module (CX24) [Change from baseline Quality of Life questionnaire (QLQ) cervical cancer module (CX24) at 1-month post-treatment]
4. Patients Global Impression of Improvement [At 1-month post-treatment]
5. International Consultation on Incontinence Questionnaire Short Form/Female Lower Urinary tract Symptoms (ICIQ-FLUTS) [Change from baseline International Consultation on Incontinence Questionnaire Short Form/Female Lower Urinary tract Symptoms (ICIQ-FLUTS) at 1-month post-treatment]
6. King's Health Questionnaire (KHQ) [Change from baseline King's Health Questionnaire at 1-month post-treatment]
7. Female Sexual Function Index [Change from baseline Female Sexual Function Index at 1-month post-treatment]
8. Vaginal Maturation Value [Change from baseline Vaginal Maturation Value at 1-month post-treatment]
9. Vaginal Health Index Score [Change from baseline Vaginal Health Index Score at 1-month post-treatment]
10. Partner Performance Questionnaire [Change from baseline Partner Performance Questionnaire at 1-month post-treatment]